Edition:
India

Stryker Corp (SYK.N)

SYK.N on New York Stock Exchange

175.15USD
23 May 2018
Change (% chg)

$2.25 (+1.30%)
Prev Close
$172.90
Open
$172.35
Day's High
$175.37
Day's Low
$172.35
Volume
107,759
Avg. Vol
357,937
52-wk High
$175.37
52-wk Low
$137.70

Latest Key Developments (Source: Significant Developments)

Stryker Corp Q1 Earnings Per Share $1.16
Friday, 27 Apr 2018 

April 26 (Reuters) - Stryker Corp ::REG-STRYKER REPORTS FIRST QUARTER 2018 OPERATING RESULTS.SEES Q2 ADJUSTED EARNINGS PER SHARE $1.70 TO $1.75.Q1 ADJUSTED EARNINGS PER SHARE $1.68.Q1 EARNINGS PER SHARE $1.16.Q1 SALES $3.2 BILLION VERSUS I/B/E/S VIEW $3.2 BILLION.Q1 EARNINGS PER SHARE VIEW $1.60 -- THOMSON REUTERS I/B/E/S.QTRLY ORGANIC NET SALES INCREASED 7.0% DESPITE ONE LESS SELLING DAY.Q2 EARNINGS PER SHARE VIEW $1.70 -- THOMSON REUTERS I/B/E/S.SEES 2018 ORGANIC NET SALES GROWTH, THAT EXCLUDES IMPACT RELATED TO ADOPTION OF NEW REVENUE RECOGNITION STANDARD TO BE OF 6.5% TO 7.0%.SEES FY 2018 ADJUSTED EARNINGS PER SHARE $7.18 TO $7.25.STRYKER - IF FOREIGN CURRENCY EXCHANGE RATES HOLD NEAR CURRENT LEVELS, SEES NET EPS TO BE POSITIVELY IMPACTED BY ABOUT $0.02 IN Q2.STRYKER - IF FOREIGN CURRENCY EXCHANGE RATES HOLD NEAR CURRENT LEVELS, SEES NET EPS TO BE POSITIVELY IMPACTED BY ABOUT $0.08 IN FULL YEAR.FY2018 EARNINGS PER SHARE VIEW $7.13 -- THOMSON REUTERS I/B/E/S.  Full Article

Allosource & Stryker Launch Prochondrix CR, A Osteochondral Allograft
Thursday, 5 Apr 2018 

April 4 (Reuters) - Allosource ::SAYS CO, STRYKER LAUNCH PROCHONDRIX CR, A OSTEOCHONDRAL ALLOGRAFT WHICH IS A NATURAL SOLUTION FOR PATIENTS NEEDING ARTICULAR CARTILAGE REPAIR.  Full Article

3D Systems Corp, Stryker Announce Exclusive Distribution Partnership
Wednesday, 17 Jan 2018 

Jan 17 (Reuters) - 3D Systems Corp ::3D SYSTEMS - CO, STRYKER ANNOUNCED EXCLUSIVE DISTRIBUTION PARTNERSHIP FOR VSP & ANATOMICAL MODELS FOR CRANIOMAXILLOFACIAL SPECIALTY.3D SYSTEMS - AGREEMENT BETWEEN CO, STRYKER IS SPECIFIC TO U.S., CANADA, EUROPE, AUSTRALIA.  Full Article

BRIEF-Vexim 2017 Sales Up 17 Pct To 21.6 Million Euros
Friday, 12 Jan 2018 

Refiles to add missing 4th bullet.:VEXIM: +17% GROWTH IN SALES IN 2017 UP TO €21.6 MILLION.‍2017 SALES RESULTS PERFORMS BELOW EXPECTATIONS OF MANAGEMENT WHICH ANTICIPATED AN ANNUAL GROWTH OF +30%​.‍PROFITABILITY TARGET FOR 2017 WILL NOT BE ACHIEVED.FY ‍FINANCIAL RESULT WILL BE ADVERSELY AFFECTED BY EUR 5 MLN EXCEPTIONAL EXPENSES, PART OF OPERATION WITH STRYKER​.  Full Article

Stryker Expects 2017 Adj Net Earnings Per Diluted Share To Be Toward High End Of Previous Range Of $6.45-$6.50​
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Stryker Corp ::STRYKER - EXPECT 2017 ADJUSTED NET EARNINGS PER DILUTED SHARE TO BE TOWARD HIGH END OF PREVIOUSLY ANNOUNCED RANGE OF $6.45 TO $6.50​.- EXPECT 2017 ADJUSTED NET EARNINGS PER DILUTED SHARE TO BE TOWARD HIGH END OF OUR PREVIOUSLY ANNOUNCED RANGE OF $6.45 TO $6.50​.- WITH RESPECT TO U.S. TAX REFORM, ANTICIPATE A MODEST HEADWIND FOR 2018.STRYKER - ‍FOREIGN CURRENCY EXCHANGE IMPACT ON NET SALES IN Q4 WAS POSITIVE OF ABOUT 1.2 PERCENT AND NOMINAL IN FULL YEAR​.REG-STRYKER PROVIDES 2017 PRELIMINARY NET SALES RESULTS.Q4 SALES $3.5 BILLION VERSUS I/B/E/S VIEW $3.39 BILLION.STRYKER SAYS PRELIMINARY ORTHOPAEDICS NET SALES OF $1.3 BILLION AS REPORTED IN Q4.- ‍PRELIMINARY DOMESTIC NET SALES OF $2.5 BILLION AND $9.1 BILLION INCREASED 9.3% AND 10.1% AS REPORTED IN Q4 AND FULL YEAR​.- ‍PRELIMINARY INTERNATIONAL NET SALES OF $1.0 BILLION AND $3.4 BILLION INCREASED 11.7% AND 9.4% AS REPORTED IN Q4 AND FULL YEAR​.Q4 REVENUE VIEW $3.39 BILLION -- THOMSON REUTERS I/B/E/S.FY2017 EARNINGS PER SHARE VIEW $6.47 -- THOMSON REUTERS I/B/E/S.  Full Article

Entellus Medical Says Deal May Require Co To Pay Stryker A Termination Fee Of $20.5 Mln
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Entellus Medical Inc ::ENTELLUS MEDICAL SAYS DEAL PROVIDES CO MAY BE REQUIRED TO PAY STRYKER TERMINATION FEE OF $20.5 MILLION UNDER CERTAIN CIRCUMSTANCES - SEC FILING.  Full Article

Stryker to buy Entellus Medical for $24.00/share in cash
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Entellus Medical Inc ::ENTELLUS MEDICAL ANNOUNCES DEFINITIVE AGREEMENT TO BE ACQUIRED BY STRYKER CORPORATION FOR A PURCHASE PRICE OF $24.00 PER SHARE IN CASH.DEAL FOR EQUITY VALUE OF ABOUT $662 MILLION.‍ENTELLUS BOARD OF DIRECTORS UNANIMOUSLY APPROVED ENTERING INTO AGREEMENT​.  Full Article

Stryker declares $0.47 per share quarterly dividend
Thursday, 7 Dec 2017 

Dec 6 (Reuters) - Stryker Corp ::STRYKER INCREASES DIVIDEND 11%, DECLARING A $0.47 PER SHARE QUARTERLY DIVIDEND.  Full Article

Stryker receives U.S. FDA HDE approval for the Neuroform Atlas stent system to treat wide neck aneurysms
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Stryker Corp :Stryker receives U.S. FDA HDE approval for the Neuroform Atlas™ stent system to treat wide neck aneurysms.Stryker Corp - ‍Approval allows company to begin U.S. commercialization efforts for Neuroform Atlas stent system​ immediately.  Full Article

Stryker Corp reports Q3 earnings per share $1.14
Friday, 27 Oct 2017 

Oct 26 (Reuters) - Stryker Corp :Stryker reports third quarter 2017 results.Sees Q4 adjusted earnings per share $1.92 to $1.97.Q3 adjusted earnings per share $1.52.Q3 earnings per share $1.14.Q3 sales $3.0 billion versus I/B/E/S view $2.97 billion.Q3 earnings per share view $1.50 -- Thomson Reuters I/B/E/S.Stryker Corp - ‍expect 2017 organic net sales growth to be in range of 6.5 pct to 7.0 pct​.Stryker Corp - ‍expect adjusted 2017 net earnings per diluted share to be in range of $6.45 to $6.50​.Fy2017 earnings per share view $6.44, revenue view $12.29 billion -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Stryker Corp Q1 Earnings Per Share $1.16

* Q1 EARNINGS PER SHARE VIEW $1.60 -- THOMSON REUTERS I/B/E/S